VRDN
Viridian Therapeutics, Inc. · Healthcare
Insiders bought $30.0M of Viridian Therapeutics, Inc. in the last 12 months
1 insider bought on 2 days.
VRDN over the last year
Largest buyers, last 12 months
VRDN after insider buys
3 months after each buy, from the first price a copier could get.
10 buys since 2021 with 3 months of prices.
Every filing
27 insider filings since 2021, newest first
Fairmount Funds Management LLC · Director and 10% owner
Fairmount Funds Management LLC · Director and 10% owner
Thomas W. Beetham · COO
Stephen F. Mahoney · President and CEO
Fairmount Funds Management LLC · Director and 10% owner
Fairmount Funds Management LLC · 10% owner
Lara Meisner · General Counsel
Lara Meisner · General Counsel
Scott Dunseth Myers · CEO
Scott Dunseth Myers · CEO
Lara Meisner · General Counsel and Secretary
Jonathan Violin · Chief Exec Officer
Lara Meisner · General Counsel and Secretary
Barrett Katz · Chief Medical Officer
Barrett Katz · Chief Medical Officer
Lara Meisner · General Counsel and Secretary
Lara Meisner · General Counsel and Secretary
Lara Meisner · General Counsel and Secretary
Lara Meisner · General Counsel and Secretary
Fairmount Funds Management LLC · 10% owner
Jonathan Violin · Chief Exec Officer
Jonathan Violin · CEO
Jonathan Violin · Chief Exec Officer
Jonathan Violin · Chief Exec Officer
Jonathan Violin · Chief Exec Officer
Frazier Life Sciences Public Fund, L.P. · 10% owner
Fairmount Funds Management LLC · Director and 10% owner
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.